A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

NCT02215447 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

4

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastrointestinal Neuroendocrine Carcinomas

Interventions

DRUG: NAB paclitaxel
DRUG: Carboplatin

Sponsor

Barwon Health

Collaborators

[object Object]
[object Object]
[object Object]